emerg
reemerg
zoonot
viral
diseas
major
threat
global
health
econom
stabil
nation
secur
vaccin
key
reduc
coronavir
diseas
burden
howev
util
liveattenu
vaccin
limit
risk
revers
repair
histori
emerg
event
due
preval
zoonot
pool
design
liveattenu
coronaviru
vaccin
rapidli
broadli
implement
essenti
outbreak
prepared
show
coronavirus
complet
rewir
transcript
regulatori
network
trn
effect
vaccin
sarscov
trnrewir
virus
attenu
protect
lethal
sarscov
challeng
rewir
trn
revert
via
secondsit
mutat
upon
serial
passag
rewir
trn
stabl
suggest
extens
rewir
trn
might
essenti
avoid
growth
select
summari
rewir
trn
feasibl
strategi
limit
revers
effect
liveattenu
coronaviru
vaccin
candid
potenti
portabl
across
nidoviral
order
merg
reemerg
zoonot
viral
diseas
major
threat
global
human
health
econom
stabil
nation
secur
incid
human
zoonot
diseas
estim
surpass
billion
case
per
year
novel
emerg
infecti
diseas
accru
hundr
billion
dollar
econom
loss
loss
greatli
magnifi
new
emerg
virus
coronavirus
cov
devast
econom
critic
livestock
popul
across
globe
continu
encroach
human
popul
anim
habitat
close
contact
domest
anim
zoonos
continu
increas
human
livestock
popul
number
densiti
expand
next
centuri
fact
recent
studi
recogn
major
emerg
infecti
diseas
event
origin
wildlif
underscor
import
develop
broadli
applic
strategi
vaccin
design
viru
famili
harbor
within
extens
zoonot
pool
vaccin
well
establish
capac
reduc
viral
diseas
burden
liveattenu
vaccin
elicit
balanc
innat
adaptiveand
often
lifelongprotect
immun
respons
includ
lactogen
immun
ideal
candid
vaccin
develop
human
anim
howev
util
broadli
applic
vaccin
platform
long
limit
risk
revers
attenu
vaccin
strain
virul
larg
stabil
attenu
clearli
evalu
assur
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
middleeast
respiratori
syndrom
coronaviru
merscov
centuri
emphas
threat
pandem
viral
infect
origin
crossspeci
transmiss
event
highli
pathogen
variant
prime
model
develop
broadbas
strategi
evalu
live
viru
vaccin
nidoviral
order
coronavirus
cov
reproduc
conserv
replic
strategi
emphas
strength
rapidli
adapt
potenti
vaccin
design
platform
take
advantag
biolog
cov
replic
transcrib
subgenom
rna
sgrna
via
discontinu
transcript
mechan
mediat
transcript
regulatori
sequenc
trss
seri
conserv
nucleotid
sequenc
posit
near
genom
sever
locat
immedi
downstream
open
read
frame
orf
fig
trss
regul
transcript
attenu
program
via
basepair
interact
leader
tr
bodi
trss
result
product
sgrna
downstream
orf
translat
within
tr
core
sequenc
acgaac
sarscov
guid
basepair
duplex
format
nascent
rna
leader
tr
collect
tr
arrang
transcript
regulatori
network
trn
conserv
laboratori
shown
possibl
rewir
guid
sequenc
sarscov
trn
produc
infecti
viru
also
show
recombin
rewir
trn
viru
wildtyp
wt
sarscov
viabl
indic
recombinationmedi
revers
cov
vaccin
platform
featur
rewir
trn
highli
unlik
base
conserv
trn
biolog
across
cov
report
explor
feasibl
develop
stabli
attenu
vaccin
platform
featur
complet
rewir
trn
candid
strategi
broadli
applic
rapidli
implement
cov
vaccin
platform
highli
resist
recombin
repair
stabli
attenu
young
highli
vulner
mous
model
human
diseas
trn
mutant
attenu
virul
previou
studi
laboratori
demonstr
sarscov
trn
could
reprogram
provid
individu
trss
replac
match
sequenc
rewir
trn
replac
conserv
tr
cassett
use
character
cov
encod
net
chang
nt
acgaac
ccggau
previou
work
show
rewir
trn
refractori
recombin
wt
genom
therefor
test
replic
pathogenesi
young
age
balbc
mice
consist
earlier
report
wt
sarscov
caus
weight
loss
age
anim
contrast
replic
caus
weight
loss
young
mice
fig
minim
weight
loss
age
balbc
mice
fig
young
mice
p
titer
wilcoxon
test
p
weight
loss
mannwhitney
test
old
mice
p
titer
p
weight
loss
wt
recombin
virus
replic
high
titer
detect
day
postinfect
pi
young
age
anim
titer
begin
clear
day
pi
fig
usual
observ
mice
infect
sarscov
vaccin
protect
mice
challeng
high
replic
titer
low
absent
virul
young
age
mous
model
pair
inher
recombinationrefractori
genom
suggest
viru
would
ideal
vaccin
candid
test
efficaci
protect
homolog
heterolog
challeng
viru
administ
mice
singledos
vaccin
alongsid
viral
replicon
particl
vrp
express
viral
spike
attach
protein
vrp
control
day
postvaccin
mice
challeng
either
mouseadapt
sarscov
challeng
sarscov
express
spike
gene
himalayan
palm
civet
paguma
larvata
strain
heterolog
challeng
mice
observ
morbid
mortal
surviv
anim
euthan
day
pi
upon
homolog
challeng
crg
vaccin
protect
weight
loss
mortal
young
age
mice
detect
viral
titer
lung
day
pi
contrast
pb
vrp
subcutan
vaccin
fig
supplementari
fig
importantli
heterolog
challeng
vrp
vaccin
crg
vaccin
induc
sarscov
neutral
antibodi
titer
approach
log
young
age
mice
nearli
higher
titer
induc
vrp
vaccin
p
twoway
anova
supplementari
fig
moreov
crg
vaccin
larg
protect
age
mice
extens
inflammatori
cell
infiltr
tissu
damag
perivascular
cuf
edema
septal
thicken
observ
pbsand
vrpsvaccin
mice
supplementari
fig
revert
pandemicassoci
mutat
liveattenu
vaccin
candid
demonstr
phenotyp
stabil
infect
host
popul
therefor
test
resist
revers
virul
subject
five
independ
serial
passag
parallel
wt
sarscov
age
balbc
mice
cours
six
passag
passag
virus
acquir
virul
phenotyp
weight
loss
percent
surviv
curv
mirror
kinet
rate
emerg
virul
seen
wt
passag
virus
supplementari
fig
attempt
identifi
genotyp
caus
phenotyp
revers
virul
genom
independ
plaqu
isol
passag
virus
wt
submit
sanger
sequenc
surprisingli
contrari
expect
mutat
either
spike
membran
proteinboth
target
mutat
select
separ
adapt
sarscov
urbani
mice
fig
identifi
wt
revert
instead
isol
show
evid
often
larg
delet
accessori
orf
fig
b
delet
often
infram
reminisc
sever
incid
host
rangeassoci
delet
identifi
human
isol
sarscov
epidem
includ
delet
rel
himalayan
palm
civet
strain
delet
region
contrast
delet
accessori
orf
rare
virul
wt
revert
rather
scatter
nonsynonym
mutat
identifi
notabl
wt
revert
exhibit
small
delet
collect
find
demonstr
region
sarscov
genom
inher
unstabl
subject
replic
pressur
especi
age
anim
indic
trnrewir
viru
would
requir
addit
stabil
mutat
feasibl
vaccin
candid
attenu
sarscov
mutant
trn
replac
demonstr
secondsit
revers
virul
upon
passag
suggest
ideal
trnrewir
vaccin
candid
would
one
would
less
like
phenotyp
revert
vivo
cov
tr
network
fine
tune
regul
express
highli
abund
lowfrequ
mrna
transcript
thu
small
chang
tr
might
subtli
alter
regul
subgenom
transcript
moreov
exact
regulatori
milieu
around
tr
uncertain
beyond
recognit
upand
downstream
sequenc
influenc
mrna
express
effici
perhap
trn
sequencespecif
manner
hypothes
extens
remodel
tr
network
may
better
disrupt
fine
tune
network
abund
lowfrequ
transcript
alter
natur
regul
global
gene
express
therebi
lead
decreas
virul
addit
possibl
virul
observ
isol
due
least
part
mous
adapt
passag
therefor
evalu
effect
extens
trn
rewir
lethal
pathogen
model
stabil
trn
recombin
repair
mutat
select
trn
mutant
construct
featur
follow
set
fig
replac
yield
infecti
viru
capabl
replic
titer
equival
mouseadapt
wt
background
viru
though
pinpoint
plaqu
phenotyp
remain
stabl
tissu
cultur
passag
replac
virul
backbon
also
gener
control
trnrewir
viru
northern
blot
analysi
versu
reveal
viru
produc
expect
band
similar
proport
wt
viru
although
addit
lowabund
transcript
also
note
supplementari
fig
virus
evalu
replic
virul
young
age
balbc
mice
comparison
young
mice
attenu
compar
caus
infect
age
balbc
mice
log
log
log
pfu
emphas
attenu
virul
phenotyp
pfu
infect
caus
almost
weight
loss
cours
infect
despit
replic
titer
log
log
pfu
infect
fig
infect
mice
infect
log
log
pfu
mice
infect
log
pfu
surviv
cours
infect
contrast
mice
infect
log
pfu
surviv
infect
mice
infect
log
log
pfu
surviv
day
pi
maximum
respect
p
logrank
test
fig
serial
passag
young
balbc
mice
contrast
rapid
phenotyp
revers
observ
remain
phenotyp
stabl
passag
mice
lose
minim
amount
start
weight
infect
throughout
passag
supplementari
fig
viral
titer
also
remain
stabl
passag
log
pfu
detect
day
pi
passag
supplementari
fig
furthermor
serial
passag
independ
three
time
six
passag
age
mice
replic
passag
condit
revert
virul
exhibit
increas
virul
caus
weight
loss
infect
anim
mortal
upon
infect
balbc
mice
pfu
postpassag
essenti
replic
mortal
shown
age
mice
infect
nonpassag
viru
distinct
mortal
caus
wildtyp
infect
age
mice
see
fig
supplementari
fig
supplementari
tabl
final
evalu
capac
protect
lethal
challeng
age
mice
mice
vaccin
log
pfu
either
exonma
previous
demonstr
effect
vaccin
backbon
age
balb
c
mous
model
sarscov
pathogenesi
day
postvaccin
mice
challeng
lethal
dose
log
pfu
evalu
weight
loss
mice
lost
minim
amount
start
weight
vaccin
p
virus
versu
pb
vaccin
wilcoxon
test
indic
exonma
equal
protect
lethal
challeng
fig
liveattenu
vaccin
remain
key
player
reduc
global
diseas
burden
associ
viral
infect
human
critic
import
livestock
companion
anim
histor
contemporarili
liveattenu
vaccin
use
success
help
control
measl
mump
rubella
polio
yellow
fever
chickenpox
infect
outbreak
howev
liveattenu
vaccin
also
associ
risk
revers
either
mutationor
recombinationdriven
process
caus
danger
outbreak
unvaccin
popul
includ
anim
exampl
highli
pathogen
porcin
epidem
diarrhea
viru
pedv
strain
emerg
china
circumv
exist
vaccin
rna
recombin
event
wildtyp
liveattenu
pedv
avian
infecti
bronchiti
viru
ibv
strain
seed
new
outbreak
therefor
measur
need
stabil
liveattenu
vaccin
revers
select
pressur
particularli
virus
like
cov
employ
recombin
standard
featur
replic
cycl
incident
recombin
event
context
coinfect
could
unintent
introduc
allel
enhanc
virul
attenu
vaccin
genom
consequ
could
difficult
predict
sever
group
includ
develop
novel
strategi
fidel
regul
control
attenu
rna
viru
pathogenesi
case
cov
develop
mutant
prevent
revers
repair
virul
recombin
repair
wellcharacter
process
essenti
genom
evolut
mani
biolog
system
play
critic
role
spread
virul
pathogenesi
gener
strategi
engin
recombinationresist
rna
virus
limit
cov
lesser
extent
enterovirus
context
cov
infect
recombin
occur
viral
rnadepend
rna
polymeras
rdrp
switch
templat
nascent
rna
synthesi
use
nascent
rna
primer
rdrp
reassoci
templat
genom
likelihood
recombin
event
occur
regul
sever
viral
factor
includ
replic
rate
rna
secondari
structur
genom
size
natur
replicas
transcriptas
protein
complex
howev
herit
recombin
occur
mediat
replic
fit
result
progeni
genom
sever
report
describ
emerg
cov
enhanc
virul
upon
genom
analysi
clearli
origin
recombin
event
relat
virus
avian
mammalian
host
includ
sarscov
furthermor
reservoir
speci
bat
prevail
evid
suggest
potenti
lethal
human
cov
sarscov
merscov
emerg
shown
harbor
multipl
cov
speci
recombin
rna
genom
frequent
identifi
within
coloni
among
individu
infect
anim
increas
likelihood
recombinationdriven
alter
speci
specif
virul
thu
engin
element
render
genom
recombinationrefractori
essenti
step
toward
ensur
liveattenu
vaccin
candid
regain
virul
incident
coinfect
anoth
trncompat
cov
genom
sarscov
highli
pathogen
pneumoenter
pathogen
captur
mani
diseas
featur
seen
among
cov
trn
conserv
sequenc
cs
motif
util
background
ccggau
uggucgc
respect
uniqu
sequenc
motif
compar
known
cov
genom
trn
sequenc
greatli
reduc
like
elimin
possibl
recombin
unmodifi
genom
canon
tr
loci
previou
work
demonstr
introduc
mismatch
trss
lethal
rna
recombin
viru
replic
furthermor
show
trn
replac
revert
primari
site
mutat
indic
rewir
trn
stabl
suffici
select
pressur
revert
even
vivo
coordin
interact
requir
trn
function
trn
revers
unlik
given
requir
nearli
simultan
revers
multipl
site
across
genom
largers
tr
css
nt
within
trn
may
prove
effect
evolut
appear
select
cov
rna
polymeras
heavili
focus
recogn
tr
cs
within
trn
regul
subgenom
transcript
attenu
result
trn
rewir
like
attribut
alter
viral
transcript
profil
lowabund
transcript
either
encod
reduc
express
previous
unidentifi
outoffram
orf
viral
host
factor
interact
viral
genom
rewir
trn
produc
obviou
novel
viral
rna
speci
supplementari
fig
novel
rna
speci
may
serv
function
mrna
produc
noncanon
viral
protein
product
attenu
viral
replic
pathogenesi
altern
novel
rna
speci
may
compet
canon
viral
rna
speci
replic
transcript
attenu
viral
replic
andor
pathogenesi
due
alter
avail
transcript
encod
bona
fide
viral
virul
factor
furthermor
rewir
trn
may
serv
attenu
factor
viru
discontinu
transcript
program
alter
program
rnaprotein
interact
involv
viral
host
protein
either
directli
ie
alter
base
requir
rnaprotein
interact
indirectli
ie
chang
rna
secondari
structur
affect
steric
avail
rnaprotein
interact
site
moreov
di
et
al
arteriviru
model
use
nextgener
sequenc
analysi
show
noncanon
transcript
produc
cours
wildtyp
infect
indic
code
capac
nidovirus
actual
much
larger
character
use
sanger
sequenc
biochem
detect
method
find
suggest
attenu
via
trn
may
abl
target
noncanon
rna
speci
might
abl
impact
pathogenesi
fewer
effect
replic
structur
protein
product
fascin
possibl
focu
futur
studi
mechan
trnrelat
attenu
hypothesi
alter
express
profil
canon
viral
rna
speci
protein
product
attenu
pathogenesi
strengthen
pair
observ
type
mutat
select
upon
passag
age
mice
mutat
profil
differ
select
occur
young
versu
age
popul
frieman
et
al
previous
demonstr
mutat
spike
nonstructur
protein
repetit
select
sever
independ
passag
mutat
confer
virul
young
day
postinfect
mice
suggest
spikevir
receptor
interact
protein
interact
import
virul
sever
ill
sarscovinfect
human
predominantli
year
age
delet
around
identifi
discuss
earlier
delet
differ
accessori
orf
frequent
observ
chang
select
age
anim
furthermor
age
mice
nearli
combin
allel
shown
fig
also
confer
increas
virul
like
reflect
increas
suscept
age
mice
lethal
outcom
data
suggest
cov
adapt
virul
differ
young
age
anim
especi
coupl
variat
viru
pathogen
determin
immun
senesc
enhanc
viru
virul
data
support
novel
hypothesi
virul
zoonot
coronavirus
may
emerg
quickli
vivo
passag
especi
age
multipl
evolutionari
pathway
exist
program
viru
virul
disproportion
identif
mutat
accessori
orf
follow
passag
trn
viru
age
anim
may
reflect
role
accessori
orf
hypothes
play
modul
host
immun
age
anim
immun
system
respond
differ
usual
sever
microbi
challeng
immun
respons
skew
toward
sever
innat
immun
effect
defect
adapt
immun
howev
context
cov
infect
augment
immun
respons
present
context
accessori
orf
delet
may
serv
virul
fulcrum
balanc
pois
essenti
immun
recognit
sever
diseas
possibl
due
defect
spread
persist
potenti
effect
host
immun
argu
stabl
vaccin
candid
consid
potenti
chang
accessori
orf
welldesign
vaccin
candid
includ
genet
trap
either
independ
attenu
trigger
recombin
event
previous
demonstr
stabl
attenu
protect
lethal
challeng
inactiv
exonucleas
activ
addit
et
al
demonstr
partial
delet
murin
hepat
viru
mhv
replicas
protein
could
protect
homolog
heterolog
challeng
combin
allel
render
viru
recombinationrefractori
alter
rna
replic
fidel
result
alter
host
immun
respons
could
produc
stabl
reversionproof
liveattenu
virus
induc
robust
neutral
immun
attenu
allel
coupl
rewir
trn
anticip
increas
stabil
attenu
minim
chanc
rna
recombin
repair
strategi
report
herein
coupl
avail
new
molecular
clone
cov
caus
sever
diseas
livestock
popul
provid
vehicl
improv
live
viru
vaccin
design
may
also
possibl
tune
cov
trn
attenu
chang
concentr
virul
allel
accessori
gene
known
impact
pathogenesi
alter
potenti
greater
enhanc
stabil
vaccin
candid
particularli
consid
tr
context
outsid
core
sequenc
studi
would
benefit
rna
structur
also
consid
tr
access
like
modul
structur
element
cov
rna
genom
studi
focu
futur
work
continu
identif
zoonot
pool
cov
genet
resembl
lethal
human
anim
cov
often
percentag
point
differ
zoonot
lethal
human
sequenc
necess
rapidli
implement
univers
attenu
platform
cov
liveattenu
vaccin
design
underscor
report
describ
design
implement
cov
attenu
strategi
easili
rapidli
adapt
cov
genom
presenc
character
trss
within
cov
genom
css
nt
offer
larg
complex
target
primari
site
revers
like
event
singl
recombin
event
would
decoupl
trn
express
network
recombin
would
lethal
therefor
attenu
strategi
pair
allel
resist
select
event
lead
secondsit
revers
could
bring
liveattenu
cov
vaccin
within
reach
realiz
face
evergrow
threat
new
human
anim
covbas
epidem
virus
cell
viru
stock
propag
cell
describ
viru
work
perform
biolog
safeti
cabinet
biosafeti
level
laboratori
construct
sar
plasmid
virus
plasmid
construct
mutat
introduc
sar
plasmid
f
use
cassett
gener
biobas
gener
sarsf
plasmid
contain
trn
mutat
mouseadapt
mutat
nt
mouseadapt
mutat
clone
f
trn
plasmid
via
pcr
restrict
digest
strategi
gener
sarsf
plasmid
contain
trn
mutat
mouseadapt
mutat
nt
mouseadapt
mutat
clone
f
trn
plasmid
via
pcr
restrict
digest
strategi
plasmid
fbstz
rmamut
fmamut
rmsc
use
gener
amplicon
result
amplicon
restrictiondigest
bsmb
ligat
purifi
ligat
amplicon
parent
vector
restrictiondigest
msc
ligat
ligat
vector
transform
topten
e
coli
cell
result
coloni
screen
sequenceverifi
virus
construct
describ
ref
northern
blot
analysi
intracellular
rna
isol
use
ribopur
reagent
ambion
austin
tx
h
postinfect
mrna
isol
use
qiagen
oligotex
mrna
isol
kit
treat
glyoxal
separ
agaros
gel
use
northernmaxgli
ambion
rna
transfer
brightstarplu
membran
ambion
h
crosslink
use
uv
light
prehybrid
probe
n
genespecif
oligonucleotid
probe
b
b
ccct
b
ct
b
gc
b
biotinyl
nucleotid
denot
superscript
b
blot
hybrid
overnight
wash
lowand
highstring
buffer
incub
phosphataseconjug
streptavidin
blot
incub
cdpstar
overlaid
film
develop
mous
infect
sarscov
mutant
experiment
protocol
involv
mice
review
approv
institut
anim
care
use
committe
univers
north
carolina
chapel
hill
nc
usa
follow
mice
use
femal
balbc
charl
river
laboratori
wilmington
usa
femal
balbc
harlan
laboratori
indianapoli
usa
mice
lightli
anesthet
infect
intranas
vari
dose
pfu
depend
experi
sarscov
trn
mutant
mice
weigh
daili
certain
day
specifi
experi
mous
lung
harvest
viru
titer
andor
rna
serial
passag
inocul
passag
subsequ
passag
inocul
clarifi
lung
homogen
lung
homogen
ml
pb
previou
passag
experi
use
minimum
n
mice
per
viru
per
dosagecondit
applic
per
timepoint
infectionchalleng
studi
mice
infect
pfu
indic
vaccin
viru
weigh
day
follow
initi
infect
challeng
lethal
dose
pfu
challeng
infect
determin
viru
titer
infect
mous
lung
lung
harvest
viru
titer
weigh
homogen
ml
pb
rpm
magnalys
roch
basel
switzerland
viru
titer
determin
plaqu
assay
vero
cell
determin
viral
neutral
antibodi
titer
mous
sera
heatinactiv
min
serial
dilut
pb
volum
next
pb
contain
lowconcentr
sarscov
pfu
highconcentr
sarscov
pfu
ad
serum
dilut
virusserum
mixtur
incub
min
follow
incub
viru
titer
mixtur
determin
plaqu
assay
final
calcul
plaqu
reduct
neutral
titer
prnt
valu
serum
dilut
plaqu
format
reduc
rel
viru
stock
treat
serum
viral
genom
sequenc
determin
sequenc
viral
genom
present
mous
lung
passag
plaqu
isol
lung
sampl
describ
briefli
individu
viral
plaqu
harvest
collect
agaros
plug
use
pipett
tip
agaros
plug
drop
ml
pb
allow
diffus
h
appli
confluent
monolay
cell
flask
incub
h
infect
cell
monolay
harvest
ml
trizol
firststrand
cdna
gener
describ
ref
amplicon
viral
genom
gener
describ
ref
sequenc
result
analyz
use
geneiou
biomatt
auckland
new
zealand
serial
cloner
serialbas
http
serialbas
freefrhomehomehtml
statist
analys
statist
analys
perform
use
graphpad
prism
graphpad
softwar
la
jolla
ca
usa
test
run
depend
experiment
design
specifi
text
signific
set
p
viral
genom
sequenc
dataset
avail
via
ncbi
genbank
access
identifi
data
gener
andor
analyz
current
studi
avail
correspond
author
reason
request
receiv
januari
accept
septemb
